Related Experiment Videos
Introduction: standards of antibacterial performance.
1Department of Microbiology and Infectious Disease, City Hospital and University of Nottingham, Nottingham NG5 1PB, UK. r.finch@nottingham.ac.uk
Summary
Antimicrobial drug development is evolving, with pharmacokinetics and pharmacodynamics guiding new therapies. Optimizing existing antimicrobial agents and developing new formulations are crucial for combating resistance and improving patient outcomes.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Antimicrobial agent development and clinical use are constantly advancing.
- Antimicrobial resistance (AMR) is a significant factor in drug development and treatment selection.
- Pharmacokinetic (PK) and pharmacodynamic (PD) parameters are increasingly vital for defining performance targets of antimicrobial agents.
Purpose of the Study:
- To review antimicrobial prescribing in light of new scientific knowledge, particularly PK/PD.
- To address the evolving landscape of antimicrobial resistance, especially in respiratory pathogens.
- To explore strategies for maintaining optimal therapeutic outcomes and limiting the spread of resistant strains.
Main Methods:
- Literature review and analysis of current trends in antimicrobial drug development and clinical application.
- Examination of the role of PK/PD in setting performance targets for antimicrobial agents.
- Assessment of strategies to combat antimicrobial resistance, including new agent development and formulation optimization.
Main Results:
- New antimicrobial therapies are primarily for hospital-associated Gram-positive infections.
- Community treatment relies on established antimicrobial agents from limited classes.
- Antimicrobial resistance is evolving, necessitating updated therapeutic strategies.
Conclusions:
- Optimizing dosage regimens and antimicrobial choices based on PK/PD is essential.
- Developing new formulations of existing agents can overcome current resistance patterns.
- A multi-faceted approach, including new agent development and improved prescribing practices, is needed to manage antimicrobial resistance effectively.